Fig. 5: Evaluation of miR-221/222 levels increases risk-stratification efficacy and results in superior clinical benefit in MM prognosis. | Blood Cancer Journal

Fig. 5: Evaluation of miR-221/222 levels increases risk-stratification efficacy and results in superior clinical benefit in MM prognosis.

From: Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

Fig. 5

Kaplan–Meier survival curves for the overall survival (OS) and progression-free survival (PFS) of the patients according to miR-221/222 levels combined with response to 1st-line therapy (A, B), R-ISS stage (C, D), and high-risk cytogenetics (E, F). p values calculated by log-rank test. sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease.

Back to article page